The Richard E. Smalley Institute for Nanoscale Science and Technology was originally named the Center for Nanoscale Science and Technology. In 2005 after the passing of Professor Smalley, the Rice University Board of Trustees renamed the Institute in his honor. In this historical account, the Institute will be referred to as the Center for Nanoscale Science and Technology prior to Fall 2005 and the Smalley Institute thereafter.
CeloNova Biosciences, Inc. develops, manufactures and markets a family of products based upon the unique properties of Polyzene®-F; pairing polymer science innovation with cutting edge devices. The Company's products are used by Physician’s across the globe to improve patient outcomes in the fields of vascular intervention and embolization.
CardioMEMS is a medical device company that has developed and is commercializing a proprietary wireless sensing and communication technology for the human body. Our technology platform is designed to improve the management of severe chronic cardiovascular diseases such as heart failure and aneurysms. Our miniature wireless sensors can be implanted using minimally invasive techniques and transmit cardiac output, blood pressure and heart rate data that are critical to the management of patients.
The Sanofi Pasteur VaxDesign Campus designs, develops, and manufactures in vitro models of the human immune system. Our mission is to prevent infectious disease by forecasting vaccine responses before clinical trials, and create a competitive advantage by providing predictive in vitro immunological models and assays.
Natural-Immunogenics has a special responsibility... to bring its new generation of colloids [appropriately called "hydrosols"] to those who need it for their own health, as well as to those who attend upon the health of others.
Sovereign Silver® represents the most significant breakthrough in colloidal technology in the last 90 years. It is an omnipotent resource in the defense of health, one with which to confront the ever increasing immune challenges threatening man, even the whole of mankind.
Nanotherapeutics has significant expertise in product formulation, pre-clinical and clinical development, scale-up and cGMP manufacturing, utilizing established and proprietary techniques: NanoQUAD™, NanoDRY™, and NanoCOAT™. Our specialized proprietary techniques can improve the release rate and enhance both the rate and extent of drug uptake, thus increasing bioavailability. The consequences of these changes include more consistent drug therapy with potentially reduced dose and dose frequency requirements and fewer side effects.